Poster: MPN-343: The BET Inhibitor Pelabresib Decreases Inflammatory Cytokines, Improves Bone Marrow Fibrosis and Function, and Demonstrates Clinical Response Irrespective of Mutation Status in Myelofibrosis Patients in the Phase 2 MANIFEST Trial
Oksana Zavidij(Constellation Pharmaceuticals (United States)), Patrick Trojer(Morpho (United States)), Gozde Colak(Morpho (United States)), Jike Cui(Morpho (United States)), Patricia J. Keller(Constellation Pharmaceuticals (United States)), Horatiu Olteanu(Mayo Clinic in Arizona), Mohamed E. Salama(The University of Texas at San Antonio Health Science Center), Ruben A. Mesa(Atrium Health Wake Forest Baptist), Alessandro M. Vannucchi(Azienda Ospedaliero-Universitaria Careggi), Claire Harrison(Guy's and St Thomas' NHS Foundation Trust), Stephen T. Oh(Washington University in St. Louis), Katarina Luptakova(Tesaro (United States)), John Mascarenhas(Tisch Hospital), Raajit K. Rampal(Memorial Sloan Kettering Cancer Center), Jennifer A. Mertz(Constellation Pharmaceuticals (United States)), Srđan Verstovšek(Unknown), Dong Chen(Mayo Clinic in Arizona), Jing Wang(The University of Texas MD Anderson Cancer Center), Zehua Chen(Broad Institute), Curtis A. Hanson(Toyota Motor Corporation (Switzerland)), Jeffrey S. Humphrey, April Chiu(Mayo Clinic), Moshe Talpaz(University of Michigan)
Cited by 1
Related Papers
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Somatic <i>CALR</i> Mutations in Myeloproliferative Neoplasms with Nonmutated <i>JAK2</i>
|New England Journal of Medicine|2013|1.7k
Activating ESR1 mutations in hormone-resistant metastatic breast cancer
|Nature Genetics|2013|1.2k